Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epitranscriptomics m6A analyses reveal distinct m6A marks in tumor necrosis a (TNF-a)-treated HeLa cells

ABSTRACT: Epitranscriptomics m6A analyses reveal distinct m6A marks in tumor necrosis a (TNF-a)-treated HeLa cells

PROVIDER: PRJNA925217 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23115913.fastq.gz	Fastqsanger.gz
	SRR23115914.fastq.gz	Fastqsanger.gz
	SRR23115915.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

Epitranscriptomics m6A analyses reveal distinct m6A marks in tumor necrosis a (TNF-a)-treated HeLa cells

Project description:We have performed a epitranscriptomics study in which we first tretaed TNF-alpha in HeLa cells and DMSO was used as a negative control. Total RNA was isolated from TNF-alpha treated cells as well as control cells and apoptotic rate was determined by flow cytometry. Total RNAs were subjected to miCLIP to identify differentially m6A methylated RNAs. We then transcriptionally analyzed apoptotic genes which have differential m6A methylation in TNF-alpha tretament by qPCR. Afterthat, candidate genes were examined at the level of translation by polysome fractioantion assay.

2024-01-16 | GSE223209 | GEO

LEAD-m6A-seq data of HeLa mRNA

Project description:We applied LEAD-m6A-seq to 11 sites of HeLa mRNA to probe m6A modification at the target sites.

2020-11-01 | GSE158389 | GEO

m6A-RIP-seq of heat shock-exposed HeLa cells upon HSATIII knockdown

Project description:To investigate the effect of HSATIII lncRNA on m6A modification, we performed m6A-RIP(RNA immuno precipitation) RNA-seq from heat shock-exposed HeLa cells upon HSATIII knockdown.

2021-04-30 | GSE164200 | GEO

m6A profiles in shCTRL, shMETTL3 HeLa cells

Project description:m6A profiles in shCTRL, shMETTL3 HeLa cells

| PRJNA553776 | ENA

LEAD-m6A-seq data of HeLa mRNA

Project description:LEAD-m6A-seq data of HeLa mRNA

| PRJNA665055 | ENA

Mapping N6-methyladenosine (m6A) peaks in wild-type and METTL5 knockout (KO) HeLa cells

Project description:We report the application of MeRIP-seq to map m6A peaks in wild type and METTL5 KO HeLa cells to investigate targets of the m6A methyltransferase METTL5.

2021-05-19 | GSE174420 | GEO

MeRIPseq of m6A in HeLa synchonized cells with total RNA

Project description:MeRIPSeq of HeLa cells synchronized by a double thymidine block to obtain the cell cycle phases and work with total RNA to study m6A mark in mRNA without polyA tail RNA seq of HeLa cells synchronized by a double thymidine block to obtain the cell cycle phases and work with total RNA to study mRNA without polyA tail

2024-06-27 | GSE236863 | GEO

m6A-RIP-seq of Ascl1-induced neurons.

Project description:We performed m6A-RIPs in Ascl1-induced neurons (iNeurons) to investigate the neuronal m6A epitranscriptome. Immunoprecipitation was done twice using two different antibodies, acquired from Abcam and Synaptic Systems (SySy), allowing for a more robust detection of m6A modification marks. Additionally, RIP-seq was performed separately with intact and fragmented RNA. The former approach allowed to identify proportions of m6A-modified transcripts among the total number, while the latter approach provided the information to identify genomic coordinates of m6A peaks.

2023-07-12 | E-MTAB-9542 | biostudies-arrayexpress

Safety of Anti-tumor Necrosis Factor (TNF) Monoclonal Antibodies in Inflammatory Bowel Disease

Project description:Anti-TNF (tumor necrosis factor) monoclonal antibodies have revolutionized management of Inflammatory bowel disease. Their common features include high efficacy but also immunogenicity and increased infection risk. Since 2013, two generics or biosimilars of the first anti-TNF have been registered in Europe, which long lerm safety profile needs yet to be established. This prospective, multicenter, observational cohort study will assess safety of treatment of anti-TNF monoclonal antibodies in inflammatory bowel disease patients in Poland. Eligible are consecutive patients in whom anti-TNF is started for Crohn’s disease, ulcerative colitis or indeterminate colitis between January 1st, 2014 and December 31st, 2015. Data to be collected include demography, Montreal classification, indication to treatment, previous treatment, operations, extraintestinal manifestations and concomitant diseases. Data on response, tolerability and safety of anti-TNF and on concomitant treatment will be collected. Adverse events logs will be completed. Majority of IBD centres in Poland, pediatric and adult, academic and regional, have agreed to participate in the study. As a result of the study, the frequency of adverse events in a cohort of Polish IBD patients on various anti-TNFs will be established.

| 2161078 | ecrin-mdr-crc

Genomewide m6A mapping uncovers dynamic changes in the m6A epitranscriptome of cisplatin-treated apoptotic HeLa cells

Project description:We have performed a epitranscriptomics study in which we first tretaed DMSO as a negative control and cisplatin in HeLa cells. Total RNA was isolated from control as well as CP treated cells and apoptotic rate was determined by flow cytometry. Total RNAs were subjected to miCLIP to identify differentially m6A methylated RNAs. We then transcriptionally analyzed apoptotic genes which have differential m6A methylation in CP tretament by qPCR. Afterthat, candidate genes were examined at the level of translation by polysome fractioantion assay.

2022-10-28 | GSE188580 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data